Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Inflamm Bowel Dis

Search In Journal Title:

Abbravation: Inflammatory Bowel Diseases

Search In Journal Abbravation:

Publisher

Narnia

Search In Publisher:

DOI

10.1007/bf01602128

Search In DOI:

ISSN

1078-0998

Search In ISSN:
Search In Title Of Papers:

Seroreactivity to microbial components in Crohns

Authors: Papp Maria Altorjay Istvan Norman Gary L Shums Zakera Palatka Karoly Vitalis Zsuzsanna Foldi Ildiko Lakos Gabriella Tumpek Judit Udvardy Miklos L Harsfalvi Jolan Fischer Simon Lakatos Laszlo Kovacs Agota Bene Laszlo Molnar Tamas Tulassay Zsolt Miheller Pal Veres Gabor Papp Janos Lakatos Peter Laszlo
Publish Date: 2007/08/01
Volume: 13, Issue: 8, Pages: 984-992
PDF Link

Abstract

Maria Papp Istvan Altorjay Gary L Norman Zakera Shums Karoly Palatka Zsuzsanna Vitalis Ildiko Foldi Gabriella Lakos Judit Tumpek Miklos L Udvardy Jolan Harsfalvi Simon Fischer Laszlo Lakatos Agota Kovacs Laszlo Bene Tamas Molnar Zsolt Tulassay Pal Miheller Gabor Veres Janos Papp Peter Laszlo Lakatos Hungarian IBD Study Group Seroreactivity to microbial components in Crohns disease is associated with ileal involvement noninflammatory disease behavior and NOD2/CARD15 genotype but not with risk for surgery in a Hungarian cohort of IBD patients Inflammatory Bowel Diseases Volume 13 Issue 8 1 August 2007 Pages 984–992 https//doiorg/101002/ibd20146Antibodies directed against Saccharomyces cerevisiae ASCA perinuclear components of neutrophils pANCA and porin protein C of Escherichia coli antiOmpC are reported to be associated with disease phenotype and may be of diagnostic importance in inflammatory bowel disease IBD Since limited data are available from Eastern Europe we assessed the above antibodies in Hungarian IBD patientsIn all 653 wellcharacterized unrelated consecutive IBD patients Crohns disease CD 558 m/f 263/295 duration 81 ± 107 years ulcerative colitis UC 95 m/f 44/51 duration 89 ± 98 years and 100 healthy subjects were investigated Sera were assayed for antiOmp and ASCA by enzymelinked immunosorbent assay ELISA and ANCA by indirect immunofluorescence assay IIF TLR4 and NOD2/CARD15 variants were tested by polymerase chain reaction/restriction fragment length polymorphism PCRRFLP Detailed clinical phenotypes were determined by reviewing the medical chartsAntiOmp ASCA and atypical pANCA antibodies were present in 312 593 and 138 of CD 242 137 and 485 of UC patients and in 20 16 and 56 of controls respectively ASCA and antiOmp positivity were associated with increased risk for CD odds ratio ORASCA = 765 95 confidence interval CI 437–134 OROmp = 181 95 CI 108–305 In a logistic regression analysis antiOmp and ASCA were independently associated with ileal and noninflammatory disease but not with a risk for surgery or response to steroids or infliximab A serology dosage effect was also observed ASCA and antiOmp antibodies were associated with NOD2/CARD15 in addition to a gene dosage effect No associations were found in UCSerological markers were useful in the differentiation between CD and UC in an Eastern European IBD cohort Reactivity to microbial components was associated with disease phenotype and NOD2/CARD15 genotype further supporting the role of altered microbial sensing in the pathogenesis of CD


Keywords:

References

citation journal title=Saccharomyces cerevisiae citation year=2003 citation volume=98 citation pages=22262231


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Gender and Location of CRC in IBDImplications for Surveillance Protocols
  2. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent
  3. Targeting TNF in Postoperative Recurrence of Crohn's Disease:Can We Extinguish the Fire Before It Starts?
  4. Gene Expression Profiling Identifies Mechanisms of Protection to Recurrent Trinitrobenzene Sulfonic Acid Colitis Mediated by Probiotics
  5. Adalimumab Therapy in Crohn's Disease of the Ileal Pouch
  6. Observations on Severity and Activity Indices in a Therapeutic Trial of Active Crohn's Disease
  7. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab
  8. One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis
  9. Role of diet in the development of inflammatory bowel disease
  10. Thromboembolism in pediatric inflammatory bowel disease: Systematic review
  11. Potential Oncogenic Properties of Mobilized Stem Cells in a Subpopulation of Inflammatory Bowel Disease Patients Infected with Helicobacter pylori
  12. Potential Oncogenic Properties of Mobilized Stem Cells in a Subpopulation of Inflammatory Bowel Disease Patients Infected with Helicobacter pylori
  13. Twin Studies Reveal Specific Imbalances in the Mucosaassociated Microbiota of Patients with Ileal Crohn's Disease
  14. Microbial Causation of the Chronic Idiopathic Inflammatory Bowel Diseases
  15. Babesiosis in a Patient on Infliximab for Crohn's Disease
  16. Plasma Chromogranin A in Patients With Inflammatory Bowel Disease: A Possible Explanation
  17. Effect of Adalimumab on Clinical Laboratory Parameters in Patients with Crohn's Disease: Results from the CHARM Trial
  18. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease
  19. What is the incidence, prevalence, and natural history of indeterminate colitis?
  20. Anti-tumor Necrosis Factor and Postoperative Complications in Crohn's Disease: Systematic Review and Meta-analysis
  21. Effects of T cell-induced colonic inflammation on epithelial barrier function†
  22. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis
  23. Dangers associated with endoscopic management of strictures in IBD
  24. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease†
  25. Role of the interleukin 24 in patients with ulcerative colitis
  26. Antibodies Against Cyclic Citrullinated Peptide (CCP) in Inflammatory Bowel Disease Patients With or Without Arthritic Manifestations
  27. Nitric Oxide and Colitis: Rats, Humans and Now Macaques
  28. Distinct Microbiome in Pouchitis Compared to Healthy Pouches in Ulcerative Colitis and Familial Adenomatous Polyposis
  29. Is Crohn's creeping fat an adipose tissue?
  30. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease
  31. Cyclosporine in the management of severe ulcerative colitis while breast-feeding
  32. Nailing down the shingles in IBD
  33. Local Injection of Infliximab in Symptomatic Isolated Mucosal LesionsA Novel Scenario for Endoscopic Therapy?
  34. A New Type of Strictureplasty for the Treatment of Multiple Long Stenosis in Crohn's Disease

Search Result: